- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Accu-Chek infusion set recalled
Roche recently recalled its Accu-Chek FlexLink Plus infusion sets globally because they may under-deliver insulin to patients.
Roche recently recalled its Accu-Chek FlexLink Plus infusion sets globally because they may under-deliver insulin to patients.
Some customers reported a kinked or bent tube when inserting the infusion set. “If this remains unnoticed it can result in under-delivery, leading to elevation of blood glucose levels,” said Todd Siesky, spokesman for Roche Diabetes Care. Fourteen adverse events related to the bent tube had been reported to FDA at the time of recall, according to Siesky.
More than 140,000 ACCU-CHEK FlexLink Plus infusion sets have been recalled in the United States. Siesky did not know how many sets have been recalled globally. ACCU-CHEK FlexLink Plus was launched in November 2010, and is sold directly to patients via distributors.
Other Accu-Chek infusion sets and insulin pumps are not affected by the recall and can continue to be used by patients.
Patients should return the Accu-Chek FlexLink Plus sets to their healthcare providers or caregivers. Adverse events should be reported to FDA’s MedWatch Safety Information and Adverse Reporting program at www.fda.gov/MedWatch, or call (800) 332-1088.
